Tue.Apr 05, 2022

article thumbnail

Upskilling in a digital health world

pharmaphorum

It’s no secret that digital technologies are playing a significant role when it comes to shaping the next era of healthcare. Necessity accelerated the adoption of new and sophisticated technologies and systems throughout the COVID-19 pandemic, but this seismic shift towards digital health has opened up a gap in education. To successfully navigate the potential of digital technologies in healthcare, attention must be focused on upskilling professionals in the field to equip them with the necessar

124
124
article thumbnail

Big pharma experts join forces to drive automation of data workflow

Outsourcing Pharma

Leaders from some of the industryâs most notable companies are working together to streamline and automate IDMP workflow and come up with various standards.

93
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AZ chases after PCSK9 rivals with antisense drug

pharmaphorum

AstraZeneca’s take on the PCSK9 inhibitor – an antisense drug licensed from Ionis six years ago – has cleared a proof-of-concept trial in high-risk patients with high blood cholesterol, but it remains to be seen where it will fit into the increasingly busy category. Results of the phase 2b ETESIAN trial of AZD8233 showed that the drug was effective, reducing low-density lipoprotein cholesterol (LDL-C) levels by 73% from baseline, when given as a once-monthly subcutaneous injection over 12

FDA 52
article thumbnail

Novartis announces new organizational structure

Outsourcing Pharma

Novartis has created a new organizational structure and operating model: which it says will make the company more agile and competitive.

52
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Immunocore gets EU nod for TCR cancer therapy Kimmtrak

pharmaphorum

Immunocore now has approval on both side of the Atlantic for Kimmtrak – the first cancer therapeutic based on T cell receptor (TCR) technology – after getting a green light from the European Commission. Kimmtrak (tebentafusp) has been cleared to for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), mirroring its label in the US.

article thumbnail

Novartis presents positive new data on relapsing MS treatment

Pharma Times

Data has shown that treatment with Kesimpta is associated with fewer relapses and reduced risk of worsening disability

48

More Trending

article thumbnail

Patent granted for Evonetix’s thermally-controlled DNA synthesis

Pharma Times

In contrast to conventional methods, Evonetix uses thermal control which offers greater accuracy and selectivity

48
article thumbnail

Bluebird sheds a third of its workforce to cut costs

pharmaphorum

Gene therapy specialist bluebird bio has said 30% of its workforce will lose their jobs, in a bid to conserve cash as it tried to get its lead programmes over the finish line. The biotech said it wants to eke out its financial reserves while it waits for the FDA’s verdict on betibeglogene autotemcel (beti-cel) in for beta thalassaemia and elivaldogene autotemcel (eli-cel) for cerebral adrenoleukodystrophy (CALD), both due later this year.

FDA 52
article thumbnail

Cytokinetics’ heart drug omecamtiv strikes out in heart failure trial

pharmaphorum

Cytokinetics’ hopes of resurrecting cardiac myosin inhibitor omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study. In the METEORIC-HF trial, omecamtiv was unable to show an improved performance in exercise capacity among patients with heart failure with reduced ejection fraction (HFrEF) compared to placebo.

FDA 52
article thumbnail

How to break difficult news with respect

pharmaphorum

Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. This post helps you prepare and conduct difficult yet respectful conversations with colleagues individually or in group settings. No, you don’t do that.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

AI test could predict best cancer therapies for patients

pharmaphorum

Researchers at the Institute of Cancer Research (ICR) in London have designed a prototype test that they think could be used to predict which combinations are likely to work in cancer patients within two days. The technique uses artificial intelligence (AI) to analyse protein data harvested from tumour cells, using an algorithm trained by looking at changes to 52 proteins when they are exposed to a panel of targeted anticancer drugs.

67